Skip Navigation LinksHome > January 2012 - Volume 7 - Issue 1 > Pneumatosis Cystoides Intestinalis After Gefitinib Therapy f...
Journal of Thoracic Oncology:
doi: 10.1097/JTO.0b013e3182381564
Image of the Month

Pneumatosis Cystoides Intestinalis After Gefitinib Therapy for Pulmonary Adenocarcinoma

Iwasaku, Masahiro MD*; Yoshioka, Hiroshige MD*; Korogi, Yohei MD*; Kunimasa, Kei MD*; Nishiyama, Akihiro MD*; Nagai, Hiroki MD†; Ishida, Tadashi MD, PhD*

Free Access
Article Outline
Collapse Box

Author Information

*Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki and †Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Disclosure: The authors no declare no conflicts of interest.

Address for correspondence: Hiroshige Yoshioka, MD, Department of Respiratory Medicine, Kurashiki Central Hospital, 1-1-1 Miwa, Kurashiki 710-8602, Japan. E-mail: hirotin@kchnet.or.jp

An 82-year-old female with right chest pain was referred to our hospital. She was diagnosed with adenocarcinoma of the lung with pleural dissemination and bone metastases. She was treated with oral gefitinib (250 mg once daily). At first, there was no apparent adverse event except for mild diarrhea. Two months after the first administration of gefitinib, she presented with mild abdominal pain, with the computed tomography revealing extensive intramural air within the intestinal wall, extending from the duodenum to the ascending colon, without portal venous air (Figure 1). A physical examination indicated no sign of toxicity, with the condition being presumed as pneumatosis cystoides intestinalis (PCI). Gefitinib was stopped and careful monitoring with dietary restriction was done. The symptoms gradually improved by conservative therapy and a follow-up computed tomography showed no sign of intramural air. Although gefitinib was readministered, the same episode repeated three times during gefitinib therapy.

Figure 1
Figure 1
Image Tools

PCI is a rare condition that is characterized by intramural gas in the gastrointestinal tract, and its pathogenesis is unknown.1,2 Although various chemotherapeutic agents have been reported to be associated with PCI, there have been no reports that addressed the association between PCI and gefitinib.

Back to Top | Article Outline

REFERENCES

1. Heng Y, Schuffler MD, Haggitt RC, et al. Pneumatosis intestinalis: a review. Am J Gastroenterol 1995;90:1747–1758.

2. Pear BL. Pneumatosis intestinalis: a review. Radiology 1998;207:13–19.

© 2012International Association for the Study of Lung Cancer

Login

Article Tools

Images

Share

Other Ways to Connect

Twitter
twitter.com/JTOonline

 



Visit JTO.org on your smartphone. Scan this code (QR reader app required) with your phone and be taken directly to the site.

 For additional oncology content, visit LWW Oncology Journals on Facebook.